secwatch.observer — SEC 8-K summary
======================================

Issuer:     PTC THERAPEUTICS, INC. (PTCT)
CIK:        0001070081
Form:       8-K
Filed at:   2022-10-27T23:59:59+00:00
Accession:  0001104659-22-112002
Event type: debt
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 2.03, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PTC Therapeutics secures up to $1B financing from Blackstone with $350M at close
--------------------------------------------------------------------------------

- Initial $350M at close: $300M senior secured term loan (7.25%+SOFR, 7-yr) and $50M common stock at $45.65/share.
- Additional $150M delayed draw debt available for 18 months; potential $500M further financing for BD.
- Collateral includes Translarna, Emflaza, Upstaza, sepiapterin, and vatiquinone assets.
- Standstill restrictions on Blackstone; 90-day lock-up on stock; registration rights for resale.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1070081/000110465922112002/0001104659-22-112002-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1070081/000110465922112002/tm2229086d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-112002

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer